Stocks
GlaxoSmithKline (GSK) EBITDA margin US GAAP (year values) |
|||||||||
| 2022 | 2023 | 2023 | 2024 | 2025 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | 30.0% | 31.0% | 29.9% | 21.3% | 31.8% | 34.4% | ||
| Changes by years, y/y, % | +1pp | +1pp | -1pp | -9pp | +11pp | +6.0% | |||
GlaxoSmithKline. EBITDA margin, %
GlaxoSmithKline. EBITDA margin, changes, pp
GlaxoSmithKline (GSK) EBITDA margin US GAAP (quarter values) |
||||||||
| 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | 2026Q1 | LTM ? | |||
| EBITDA margin, % | ? | 41.2% | 40.4% | 39.3% | 22.1% | 36.4% | 34.4% | |
| Changes by years, y/y, % | +3pp | +7pp | +25pp | +8pp | -5pp | |||
| Changes by quarters, q/q, % | +27pp | -1pp | -1pp | -17pp | +14pp | |||
